公开(公告)号：US20240316091A1

公开(公告)日：2024-09-26

申请号：US18680866

申请日：2024-05-31

申请人： STEADMAN PHILIPPON RESEARCH INSTITUTE

发明人： Chelsea BAHNEY ,  Ralph MARCUCIO ,  Gianluca FONTANA ,  William L. MURPHY ,  John P. COOKE ,  Daniel L. KISS ,  Francesca TARABALLI ,  Nicole EHRHART ,  Anna-Laura NELSON

IPC分类号： A61K31/7105 ,  A61P19/00 ,  C07H21/02

CPC分类号： A61K31/7105 ,  A61P19/00 ,  C07H21/02

摘要： The present disclosure is related to methods of stimulating bone formation for the purpose of improving bone repair, accelerating bone healing, and/or generating now bone in a local region with absent or diminished bone due to injury, disease, or defect, comprising administering a composition comprising β-catenin mRNA complex to the subject.

公开(公告)号：US20240285711A1

公开(公告)日：2024-08-29

申请号：US18576255

申请日：2022-07-01

申请人： Altergon S.A.

发明人： Andrea Maria Giori ,  Andrea Alimonti

IPC分类号： A61K36/537 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00

CPC分类号： A61K36/537 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00 ,  A61K2236/333 ,  A61K2236/39 ,  A61K2236/51

摘要： The present invention relates to the use of Salvia haenkei extract as an active agent in the treatment of musculoskeletal disorders, being able to offer a significant contribution in slowing, relieving, reducing and/or preventing alterations and damages of the musculoskeletal tissues. Furthermore, the present invention also relates to a pharmaceutical composition comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients, for use in the treatment of musculoskeletal disorders.

公开(公告)号：US20240285626A1

公开(公告)日：2024-08-29

申请号：US18589498

申请日：2024-02-28

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE PARIS ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  FONDATION IMAGINE

发明人： Laurence LEGEAI-MALLET

IPC分类号： A61K31/506 ,  A61P19/00

CPC分类号： A61K31/506 ,  A61P19/00

摘要： FGFR3 gain-of-function mutations are responsible for a family of chondrodysplasias namely, achondroplasia (ACH) the most common form of dwarfism, a lethal form of dwarfism thanatophoric dysplasia (TD) as well as and hypochondroplasia. Recent data demonstrate that Infigratinib (NVP-BGJ398) corrects pathological hallmarks of ACH and support it as a 10 potential therapeutic approach for FGFR3-related skeletal diseases. Now the inventors has investigated the feasibility to treat the defective growth of the skeleton during the pregnancy with the drug. They treated pregnant female Fgfr3Nco/Y67C mice with the drug (4 mg/kg) that was injected subcutaneously at day E14.5 continuing daily through day 1 (after birth). The data indicated that BGJ398 treatment during 5 days in pregnant mice successfully repressed skeletal 15 anomalies that occurred during embryonic stages. Accordingly, the present invention relates to methods for treatment of FGFR3-related skeletal diseases during pregnancy with Infigratinib.

公开(公告)号：US20240277846A1

公开(公告)日：2024-08-22

申请号：US18409423

申请日：2024-01-10

申请人： KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

发明人： Heemin KANG ,  Woo-Young JANG

IPC分类号： A61K41/00 ,  A61K33/26 ,  A61K47/54 ,  A61L27/04 ,  A61L27/12 ,  A61L27/54 ,  A61P19/00

CPC分类号： A61K41/00 ,  A61K33/26 ,  A61K47/549 ,  A61L27/042 ,  A61L27/12 ,  A61L27/54 ,  A61P19/00 ,  A61L2300/232 ,  A61L2300/412 ,  A61L2430/02

摘要： A magnetic biomolecule-metal ion self-assembly complex for treatment includes an iron ion; and at least one ligand, wherein the ligand and the iron ion are reversibly self-assembled with each other or self-disassembled from each other, wherein the ligand and the iron ion are self-assembled with each other via a first bond to form a self-assembly, wherein the self-assembling is performed by at least one of the metal ion and the ligand, wherein the self-assembly includes a plural of self-assemblies, wherein the self-assemblies adjacent to each other self-bind to each other via a second bond to form the self-assembly complex. The magnetic biomolecule-metal ion self-assembly complex is effectively used for cancer treatment, osteoarthritis treatment, and bone defect treatment.

公开(公告)号：US20240238421A1

公开(公告)日：2024-07-18

申请号：US18392543

申请日：2023-12-21

申请人： THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE ,  COLORADO SCHOOL OF MINES

发明人： Karin A. PAYNE ,  Melissa D. KREBS

IPC分类号： A61K47/36 ,  A61K9/00 ,  A61K9/06 ,  A61K47/22 ,  A61L27/20 ,  A61L27/52 ,  A61L27/54 ,  A61P19/00 ,  C07K16/22 ,  C08J3/075 ,  A61B17/16

CPC分类号： A61K47/36 ,  A61K9/0019 ,  A61K9/06 ,  A61K47/22 ,  A61L27/20 ,  A61L27/52 ,  A61L27/54 ,  A61P19/00 ,  C07K16/22 ,  C08J3/075 ,  A61B17/16 ,  A61L2300/256 ,  A61L2300/412 ,  A61L2300/414 ,  A61L2300/416 ,  A61L2300/62 ,  A61L2430/06 ,  C08J2305/04 ,  C08J2305/08

摘要： The present invention relates to the unexpected discovery of compositions and methods for the treatment of growth plate defects. In certain embodiments, the methods prevent the growth of “bony bars” at the site of growth plate injury, thereby preventing growth arrest and/or deformity. In certain embodiments, the compositions comprise hydrogels comprising at least one biological factor capable of preventing bony bar formation.

公开(公告)号：US20240207346A1

公开(公告)日：2024-06-27

申请号：US18545477

申请日：2023-12-19

申请人： Man Ki HWANG

发明人： Man Ki HWANG

IPC分类号： A61K36/481 ,  A61K36/03 ,  A61K36/254 ,  A61K36/45 ,  A61K36/53 ,  A61K36/9066 ,  A61P19/00

CPC分类号： A61K36/481 ,  A61K36/03 ,  A61K36/254 ,  A61K36/45 ,  A61K36/53 ,  A61K36/9066 ,  A61P19/00

摘要： Disclosed herein is a method for manufacturing a bone growth promoting composition including preparing a mixture by mixing Astragalus membranceus, Acanthopanax senticosus, Phlomis umbrosa, and bilberry, fermenting the mixture primarily, drying and grinding the mixture into a powder, extracting liquid from the powder, and fermenting the liquid secondarily.

公开(公告)号：US11976099B2

公开(公告)日：2024-05-07

申请号：US17393593

申请日：2021-08-04

申请人： THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD. ,  B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY

发明人： Niv Papo ,  Noam Levaot ,  Yuval Zur ,  Lior Rosenfeld

IPC分类号： C07K14/435 ,  A61K38/00 ,  A61K38/19 ,  A61P19/00 ,  C07K14/52 ,  C07K14/535 ,  C12N15/11 ,  C07K14/53

CPC分类号： C07K14/435 ,  A61K38/19 ,  A61P19/00 ,  C07K14/52 ,  C07K14/535 ,  C12N15/11 ,  A61K38/00 ,  A61K38/193 ,  C07K14/53

摘要： Mutant M-CSF protein, comprising αvβ3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.

公开(公告)号：US20240002788A1

公开(公告)日：2024-01-04

申请号：US18039372

申请日：2021-12-03

申请人： VityleBio, Inc.

发明人： Shannon Brown Fedenko ,  Isaac Finger-Baker

IPC分类号： C12N5/073 ,  A61P17/02 ,  A61P19/00

CPC分类号： C12N5/0605 ,  A61P17/02 ,  A61P19/00 ,  C12N2509/10

摘要： Disclosed herein are embodiments of an invention relating to non-human mammalian placental extract compositions, methods of extraction of compositions from non-human mammalian placenta, and methods of treatment using non-human mammalian placental compositions. These compositions have regenerative properties for medical and veterinary applications like tissue and cell culture and regeneration. These regenerative properties include anti-inflammatory, anti-oxidative, anti-microbial, pro-osteogenic, pro-angioenic, pro-neurogemc, pro-neuronal, and immune modulating, The present invention allows for effective bioburden mitigation and extraction of from non-human mammalian placenta and placenta collected in non-clinical environments for medical and veterinary applications.

公开(公告)号：US20230414561A1

公开(公告)日：2023-12-28

申请号：US18463707

申请日：2023-09-08

申请人： INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITE PARIS CITE ,  FONDATION IMAGINE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  UNIVERSIDAD DE GRANADA

发明人： Laurence LEGEAI-MALLET ,  Antonio SEGURA CARRETERO ,  Maria De La Luz CADIZ GURREA

IPC分类号： A61K31/353 ,  A61P19/00

CPC分类号： A61K31/353 ,  A61P19/00

摘要： FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (−)-epicatechin from T. cacao and showed that (−)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (−)-epicatechin for the treatment of FGFR3-related chondrodysplasias.

公开(公告)号：US20230404877A1

公开(公告)日：2023-12-21

申请号：US18028690

申请日：2021-10-19

申请人： Shiseido Company, Ltd.

发明人： Toru KINA ,  Yuuji SONOYAMA ,  Mitsuki NAKAMURA

IPC分类号： A61K8/34 ,  A61P19/00 ,  A61K8/02 ,  A61K8/86 ,  A61K8/25

CPC分类号： A61K8/345 ,  A61P19/00 ,  A61K8/025 ,  A61K2800/622 ,  A61K8/86 ,  A61K8/25 ,  A61K2800/10 ,  A61K8/0275

摘要： A powder-containing composition contains from 0.5% by mass to 22% by mass of a first powder which is a nonspherical powder having a hydrophobic particle surface, from 6% by mass to 25% by mass of a liquid-state polyol, 50% by mass or greater of water, and from 3% by mass to 12% by mass of a liquid-state oily component. A content of a second powder which is a spherical powder is 1.5 parts by mass or less relative to 1 part by mass of the first powder. A content of a surfactant is 0.5% by mass or less relative to the mass of the powder-containing composition.